Schuller G B, Morahan P S
J Natl Cancer Inst. 1979 May;62(5):1257-60.
Male BALB/c mice that received prophylactic iv treatment with pyran had significantly enhanced splenomegaly, an increased number of splenic foci induced by the spleen focus forming virus (SFFV) in the Friend murine leukemia virus (F-MuLV) complex, and a slightly decreased mean survival time as compared with untreated controls infected with F-MuLV. A corresponding increase in the lymphatic leukemia virus component of the F-MuLV complex was not observed, which suggests that the enhancement of the disease was due primarily to a selective increase in the SFFV component of the F-MuLV complex. That the enhancement was related to an increased number of target cells for SFFV was substantiated by data concerning erythropoiesis in iv pyran-treated animals. Increases in splenic hematocrits and in uptake of 59Fe in the spleens of animals treated iv with pyran provided quantitative evidence for the histologic finding of increased erythroid precursors in the spleens.
接受吡喃静脉预防性治疗的雄性BALB/c小鼠,与感染F-小鼠白血病病毒(F-MuLV)的未治疗对照相比,脾肿大显著增强,Friend小鼠白血病病毒(F-MuLV)复合物中由脾灶形成病毒(SFFV)诱导的脾病灶数量增加,平均存活时间略有缩短。未观察到F-MuLV复合物中淋巴白血病病毒成分相应增加,这表明疾病的增强主要是由于F-MuLV复合物中SFFV成分的选择性增加。静脉注射吡喃治疗动物的红细胞生成数据证实,这种增强与SFFV靶细胞数量增加有关。静脉注射吡喃治疗的动物脾脏血细胞比容增加以及脾脏对59Fe摄取增加,为脾脏中红系前体细胞增加的组织学发现提供了定量证据。